GuidelineWiener medizinische Wochenschrift. Supplement2009
[Austrian guidance for the pharmacological treatment of osteoporosis in postmenopausal women--update 2009].
Guideline in Wiener medizinische Wochenschrift. Supplement, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 16 citations in OpenAlex.
- Acupoint injection treatment for primary osteoporosis: A systematic review and meta-analysis of randomized controlled trials protocol.Medicine · 2019Article
- Economic burden of osteoporotic fractures in Austria.Health economics review · 2012Article
- [Diagnosis of osteoporosis in geriatric patients - possibilities and limitations].Wiener medizinische Wochenschrift (1946) · 2012Review
- [Austrian guidance for the pharmacologic treatment of osteoporosis in postmenopausal women: Addendum 2010].Wiener medizinische Wochenschrift (1946) · 2010Article
- An antibody against RANKL for the treatment of osteoporosis, inflammatory and malignant bone diseases.Wiener medizinische Wochenschrift (1946) · 2010Review
- Pharmacologic undertreatment of osteoporosis in Austrian nursing homes and senior's residences.Wiener klinische Wochenschrift · 2010Article
- [Osteoporosis: a challenge for prevention].Wiener medizinische Wochenschrift (1946) · 2009Article
- Osteoporosis: New-Generation Drugs.Breast care (Basel, Switzerland)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis is a systemic skeletal disease characterized by diminished bone mass and deterioration of bone microarchitecture, leading to increased fragility and subsequent increased fracture risk. Therapeutic measures therefore aim at reducing individual fracture risk. In Austria, the following drugs, all of which have been proven to reduce fracture risk, are currently registered for the treatment of postmenopausal osteoporosis: alendronate, risedronate, etidronate, ibandronate, raloxifene, teriparatide (1-34 PTH), 1-84 PTH, strontium ranelate and salmon calcitonin. Fluorides are still available, but their role in daily practice has become negligible. Currently, there is no evidence that a combination of two or more of these drugs could improve anti-fracture potency. However, treatment with PTH should be followed by the treatment with an anticatabolic drug such as bisphosphonates. Calcium and vitamin D constitute an important adjunct to any osteoporosis treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.